PR 3-9-12: FY’12/Q3 Financials (q/e 1-31-12)
”Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2012 Financial Results and Recent Developments
• Data From Seven Ongoing Bavituximab Clinical Trials Expected Throughout 2012”
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=656328
TUSTIN, CA - 3/9/12: Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced financial results for the third quarter ended January 31, 2012 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.
"This quarter we continued to advance our clinical programs toward a number of significant milestones with the potential to build considerable value in our bavituximab clinical programs, our Cotara clinical program and at our contract manufacturing subsidiary Avid Bioservices," said Steven W. King, president and CEO of Peregrine. "We expect the remainder of 2012 to yield a significant number of clinical data points from our Phase II trials in front and second-line non-small cell lung cancer, pancreatic cancer and preliminary results from all four investigator-sponsored trials in various cancers, including data from three of these studies that will be presented at the upcoming AACR meeting in early April. We are also continuing our discussions regarding possible registration trial designs for Cotara with the FDA and we expect FY 2012 to be a record revenue year for our Avid Bioservices business, an indicator of the success of our highly-valued customers. As such, we are increasing our revenue guidance to within the range of $14 to $16 million for the full fiscal year."
ONCOLOGY PROGRAM HIGHLIGHTS
Bavituximab Phase II NSCLC Trials
This morning, Peregrine announced top-line overall response rate (ORR) and current median progression free survival (PFS) estimates from its phase II trial comparing bavituximab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with front-line Stage IIIb and Stage IV non-small cell lung cancer (NSCLC). Based on these reported data, the next important data points that will allow us to plan the next steps in our clinical development strategy of bavituximab for NSCLC include, but are not limited to median overall survival ("OS") data from the front-line NSCLC study which is expected in the second half of calendar year 2012, data from our second-line NSCLC study which is expected in the first half of calendar year 2012 and data from an ongoing investigator sponsored trial (IST) evaluating bavituximab in combination with pemetrexed and carboplatin in front-line NSCLC which is expected during calendar year 2012.
Peregrine is also conducting a randomized, placebo-controlled, double-blinded trial in 121 second-line NSCLC patients evaluating bavituximab in combination with docetaxel versus placebo plus docetaxel. The trial is expected to be unblinded in the first half of 2012 to assess the trial's primary endpoint, overall response rates, according to RECIST criteria. Secondary endpoints, including PFS and OS will be reported once these data-driven events are reached.
Bavituximab Phase II Pancreatic Cancer Trial
Patient enrollment is progressing in a randomized Phase II trial in up to 70 advanced pancreatic cancer patients evaluating bavituximab plus gemcitabine versus gemcitabine alone. Patient enrollment is expected to be completed this year and interim data reported during 2012.
Bavituximab Investigator-Sponsored Trials (IST)
Patient enrollment is continuing in four ISTs evaluating bavituximab plus standard therapies in patients with HER-2 negative advanced metastatic breast cancer, advanced NSCLC, advanced liver cancer, and castration resistant advanced prostate cancer. These trials are designed to explore bavituximab's broad potential in additional treatment combinations and oncology indications. Peregrine is scheduled to present initial data from the breast cancer, NSCLC and liver cancer trials at the Annual Meeting of the American Association for Cancer Research (AACR) being held March 31-April 4, 2012.
Cotara® Clinical Program
Peregrine's single-administration approach to treating recurrent glioblastoma multiforme (GBM) has shown encouraging 9.3 month median overall survival data from a Phase II trial in 41 patients. Discussions between Peregrine and the U.S. Food and Drug Administration (FDA) are ongoing with the goal of negotiating a pivotal trial which can be executed in 2 years or less in this orphan indication. Once a final protocol has been designed, Peregrine intends to seek partners both in the U.S. and internationally to support the development of Cotara for this deadly form of brain cancer.
ANTIVIRAL PROGRAM HIGHLIGHTS
Bavituximab Phase II HCV Program
In December, Peregrine announced preliminary data from a randomized Phase II trial evaluating bavituximab plus ribavirin versus pegylated interferon alpha-2A, plus ribavirin in patients infected with genotype-1 chronic hepatitis C virus (HCV). Analysis of data from the 12-week trial indicated that the combination of bavituximab and ribavirin appeared safe and well tolerated, with patients reporting fewer side effects than in the interferon-containing arm. The trial also indicated that both dose levels of bavituximab with ribavirin demonstrated antiviral activity, with a higher early viral response (EVR) rate in patients receiving the 0.3 mg/kg dosing level. While the EVR rate was greatest in the interferon-containing group by the end of the study, based on the nature of late EVR development in the bavituximab containing arms, a longer-term evaluation is needed to adequately compare the effectiveness of bavituximab versus interferon. Peregrine is seeking a partner to further advance the program.
CORPORATE
Last week, Peregrine announced that seven posters were accepted for presentation at the AACR Annual Meeting being held March 31-April 4, 2012. These posters include initial clinical data from three ISTs of bavituximab in NSCLC, liver and breast cancers, as well as preclinical work in the areas of prostate cancer and tumor imaging.
FINANCIAL RESULTS
Total revenues for the third quarter of FY 2012 were $3,281,000, compared to $2,883,000 for the same quarter of the prior fiscal year. This increase was primarily attributable to higher contract manufacturing revenue generated by Peregrine's biomanufacturing subsidiary Avid Bioservices. Contract manufacturing revenue was $3,203,000 for the third quarter of FY 2012, compared to $1,922,000 for the same quarter of the prior fiscal year. Based on services underway and expected to complete during the remainder of FY 2012, Peregrine is revising its guidance for contract manufacturing revenue to between $14 and $16 million for FY 2012. Avid will also continue to utilize available capacity and resources as it prepares for future clinical development and potential commercialization of bavituximab and Cotara, while also seeking to grow its services from third-party clients.
Total costs and expenses in the third quarter of FY 2012 were $14,374,000, compared to $11,726,000 in the third quarter of FY 2011. The increase primarily was attributable to higher research and development expenses to advance Peregrine's multiple randomized Phase II bavituximab clinical trials in addition to increased manufacturing costs as we prepare bavituximab and Cotara for commercial scale manufacturing. For the third quarter FY 2012, research and development expenses were $9,180,000 compared to $7,053,000 for the third quarter of FY 2011.
Peregrine's consolidated net loss was $11,093,000, or $0.13 per basic and diluted share, for the third quarter of FY 2012, compared to a net loss of $8,929,000, or $0.14 per basic and diluted share, for the same quarter of the prior year.
Peregrine reported $19,761,000 in cash and cash equivalents at January 31, 2012, compared to $18,055,000 at October 31, 2011.
More detailed financial information and analysis may be found in Peregrine's Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission today.
Conference Call
Peregrine will host a conference call and webcast today, March 9, 2012, at 4:30 PM ET (1:30 PM PT).
-- To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through March 16, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 52089710.
-- To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and infectious diseases. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor *snip*
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED NINE MONTHS ENDED
JANUARY 31, JANUARY 31,
2012 2011 2012 2011
------------ ------------ ------------ ------------
Unaudited Unaudited Unaudited Unaudited
REVENUES:
Contract
manufacturing
revenue $ 3,203,000 $ 1,922,000 $ 12,796,000 $ 6,532,000
Government contract
revenue - 882,000 - 3,959,000
License revenue 78,000 79,000 372,000 272,000
------------ ------------ ------------ ------------
Total revenues 3,281,000 2,883,000 13,168,000 10,763,000
COSTS AND EXPENSES:
Cost of contract
manufacturing 2,484,000 1,726,000 9,219,000 5,885,000
Research and
development 9,180,000 7,053,000 26,758,000 21,464,000
Selling, general and
administrative 2,710,000 2,947,000 8,371,000 8,147,000
------------ ------------ ------------ ------------
Total costs and
expenses 14,374,000 11,726,000 44,348,000 35,496,000
------------ ------------ ------------ ------------
LOSS FROM OPERATIONS (11,093,000) (8,843,000) (31,180,000) (24,733,000)
------------ ------------ ------------ ------------
OTHER INCOME
(EXPENSE):
Interest and other
income 9,000 20,000 31,000 1,034,000
Interest and other
expense (6,000) (106,000) (88,000) (438,000)
------------ ------------ ------------ ------------
NET LOSS $(11,090,000) $ (8,929,000) $(31,237,000) $(24,137,000)
============ ============ ============ ============
WEIGHTED AVERAGE
COMMON SHARES
OUTSTANDING:
Basic and Diluted 87,149,770 64,374,282 78,443,114 58,497,756
============ ============ ============ ============
BASIC AND DILUTED
LOSS PER COMMON
SHARE $ (0.13) $ (0.14) $ (0.40) $ (0.41)
============ ============ ============ ============
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JANUARY 31, APRIL 30,
2012 2011
------------- -------------
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 19,761,000 $ 23,075,000
Trade and other receivables, net 2,078,000 1,389,000
Government contract receivables - 93,000
Inventories, net 2,744,000 5,284,000
Prepaid expenses and other current assets,
net 1,238,000 974,000
------------- -------------
Total current assets 25,821,000 30,815,000
Property, net 2,659,000 2,209,000
Other assets 960,000 1,742,000
------------- -------------
TOTAL ASSETS $ 29,440,000 $ 34,766,000
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 3,940,000 $ 4,046,000
Accrued clinical trial and related fees 3,042,000 2,292,000
Accrued payroll and related costs 2,098,000 1,455,000
Notes payable, current portion and net of
discount - 1,321,000
Deferred revenue 2,552,000 5,617,000
Customer deposits 2,463,000 1,759,000
Other current liabilities 1,104,000 1,189,000
------------- -------------
Total current liabilities 15,199,000 17,679,000
Deferred revenue 523,000 632,000
Other long-term liabilities 813,000 1,037,000
Commitments and contingencies
STOCKHOLDERS' EQUITY:
Preferred stock-$0.001 par value; authorized
5,000,000 shares; non-voting; nil shares
outstanding - -
Common stock-$0.001 par value; authorized
325,000,000 shares; outstanding - 93,146,226
and 69,837,142, respectively 93,000 70,000
Additional paid-in capital 340,054,000 311,353,000
Accumulated deficit (327,242,000) (296,005,000)
------------- -------------
Total stockholders' equity 12,905,000 15,418,000
------------- -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 29,440,000 $ 34,766,000
============= =============
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc., (800) 987-8256, info@peregrineinc.com
= = = = = = = = = = = = =
Latest 10K 4-30-11 iss. 7-14-11: http://tinyurl.com/3hyx5xv PR: http://tinyurl.com/6xh9geb (Cash 4-30-11 $23.1mm)
Latest 10Q 1-31-12 iss. 3-9-12 http://tinyurl.com/7h352ks PR: http://tinyurl.com/7z9qh23 (Cash 1-31-12 $19.8mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
